CO2024011229A2 - Síntesis de inhibidores de tirosina quinasa de bruton - Google Patents
Síntesis de inhibidores de tirosina quinasa de brutonInfo
- Publication number
- CO2024011229A2 CO2024011229A2 CONC2024/0011229A CO2024011229A CO2024011229A2 CO 2024011229 A2 CO2024011229 A2 CO 2024011229A2 CO 2024011229 A CO2024011229 A CO 2024011229A CO 2024011229 A2 CO2024011229 A2 CO 2024011229A2
- Authority
- CO
- Colombia
- Prior art keywords
- synthesis
- tyrosine kinase
- kinase inhibitors
- bruton tyrosine
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Health & Medical Sciences (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20220100151 | 2022-02-18 | ||
| EP22167032 | 2022-04-06 | ||
| EP22178413 | 2022-06-10 | ||
| PCT/EP2023/054043 WO2023156599A1 (en) | 2022-02-18 | 2023-02-17 | Synthesis of bruton's tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024011229A2 true CO2024011229A2 (es) | 2024-08-30 |
Family
ID=85227338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0011229A CO2024011229A2 (es) | 2022-02-18 | 2024-08-20 | Síntesis de inhibidores de tirosina quinasa de bruton |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250163076A1 (https=) |
| EP (1) | EP4479405A1 (https=) |
| JP (1) | JP2025506671A (https=) |
| KR (1) | KR20240148351A (https=) |
| AU (1) | AU2023221549A1 (https=) |
| CA (1) | CA3252338A1 (https=) |
| CL (1) | CL2024002409A1 (https=) |
| CO (1) | CO2024011229A2 (https=) |
| IL (1) | IL314902A (https=) |
| JO (1) | JOP20240182A1 (https=) |
| MX (1) | MX2024010134A (https=) |
| PE (1) | PE20242069A1 (https=) |
| WO (1) | WO2023156599A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025262118A1 (en) * | 2024-06-20 | 2025-12-26 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) * | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| WO2018103060A1 (en) * | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
-
2023
- 2023-02-17 AU AU2023221549A patent/AU2023221549A1/en active Pending
- 2023-02-17 KR KR1020247027226A patent/KR20240148351A/ko active Pending
- 2023-02-17 EP EP23705025.7A patent/EP4479405A1/en active Pending
- 2023-02-17 WO PCT/EP2023/054043 patent/WO2023156599A1/en not_active Ceased
- 2023-02-17 MX MX2024010134A patent/MX2024010134A/es unknown
- 2023-02-17 JP JP2024547937A patent/JP2025506671A/ja active Pending
- 2023-02-17 IL IL314902A patent/IL314902A/en unknown
- 2023-02-17 PE PE2024001734A patent/PE20242069A1/es unknown
- 2023-02-17 US US18/838,678 patent/US20250163076A1/en active Pending
- 2023-02-17 CA CA3252338A patent/CA3252338A1/en active Pending
-
2024
- 2024-08-12 CL CL2024002409A patent/CL2024002409A1/es unknown
- 2024-08-14 JO JOJO/P/2024/0182A patent/JOP20240182A1/ar unknown
- 2024-08-20 CO CONC2024/0011229A patent/CO2024011229A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024010134A (es) | 2024-08-27 |
| CA3252338A1 (en) | 2023-08-24 |
| KR20240148351A (ko) | 2024-10-11 |
| EP4479405A1 (en) | 2024-12-25 |
| IL314902A (en) | 2024-10-01 |
| PE20242069A1 (es) | 2024-10-18 |
| JP2025506671A (ja) | 2025-03-13 |
| JOP20240182A1 (ar) | 2024-08-14 |
| US20250163076A1 (en) | 2025-05-22 |
| WO2023156599A1 (en) | 2023-08-24 |
| AU2023221549A1 (en) | 2024-10-03 |
| CL2024002409A1 (es) | 2025-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023017661A2 (pt) | Inibidores de kras | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| MX2013002461A (es) | Compuestos y composiciones novedosos para la inhibición de nampt. | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| PE20220430A1 (es) | PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA | |
| CO2024011229A2 (es) | Síntesis de inhibidores de tirosina quinasa de bruton | |
| CL2024002895A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso. | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| MX2025012180A (es) | Sintesis de inhibidores de ras | |
| CO2025018750A2 (es) | Inhibidores de wrn | |
| CO2021000940A2 (es) | Procedimiento y productos intermedios para la preparación de bilastina | |
| UY40657A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| IL314221A (en) | Synthesis of a kif18a inhibitor | |
| CL2025002125A1 (es) | Compuestos novedosos | |
| BR112022012149A2 (pt) | Síntese de compostos para promover o crescimento do cabelo | |
| MX2023013179A (es) | Metodos para elaborar un modulador de hemoglobina. | |
| CL2023001018A1 (es) | Compuestos inhibidores de autotaxina | |
| MX2024009581A (es) | Compuestos de uracilo n3-sustituidos como inhibidores de trpa1. | |
| MX2025007840A (es) | Formas de estado sólido de inhibidores de mnk | |
| MX2025000791A (es) | Compuestos terapeuticos, formulaciones y uso de los mismos | |
| MX2022010675A (es) | Composiciones que comprenden profarmacos de metilfenidato, procesos de elaboracion y uso de los mismos. | |
| EA202092114A1 (ru) | Новый способ получения спрингена | |
| MX2021006499A (es) | Proceso de preparacion de un enol eter biciclico. | |
| CL2023003823A1 (es) | Método para preparar inhibidor de xantina oxidasa | |
| AR132901A1 (es) | Inhibidores de wrn |